IMMX Immix Biopharma, Inc.
USHealthcareAs of 2026-08-24
Why IMMX matters now
Immix Biopharma, Inc. (IMMX) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.61 with -0.37% on the session and $740.4M in market capitalization; recent performance reads 1-month -1.58% and YTD +66.73%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.1M, and EPS of $-0.18. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.9%.
The latest indexable market news headline is "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes BUCHAN JANE filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.96
P/S
0.00
EV/EBITDA
-11.46
DCF Value
$2.66
FCF Yield
-6.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.2%
ROA
-36.5%
ROIC
-42.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.1M | $-0.18 |
| Q4 2025 | $0.00 | $-10.7M | $-0.28 |
| FY 2025 | $0.00 | $-29.4M | $-0.89 |
| Q3 2025 | $0.00 | $-7.6M | $-0.24 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.00
Target (Median)
$17.00
Target Range
$14.00 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.10
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.